Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in ...
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
A UPL is the maximum reimbursement certain payers can provide pharmacies and providers for a drug. A UPL caps what a payer ...
Cancer survivors are living longer, but longer survival brings a new pressing question: who helps them live well afterward?
Dyshidrotic eczema behaves differently from other forms of hand eczema in ways that matter for how it is worked up and ...
When Erica Plybeah launched MedHaul in 2017, she didn’t just think medical transportation was a barrier to care. She’d lived ...
Postpartum navigation missed its primary goal but raised postpartum visits and primary care use among Medicaid-insured ...
A 39-year-old woman in Franklin County, Pennsylvania, died after a recent measles diagnosis in what would be the sixth ...
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
Nogapendekin alfa inbakicept-pmln (Anktiva; ImmunityBio Inc) given with Bacillus Calmette-Guérin (BCG) is now the first ...
Iberdomide (Zenbexus; Bristol Myers Squibb) in combination with daratumumab and dexamethasone (ZDd) demonstrated a statistically significant improvement in the dual-primary end po ...
Eliot F. Battle, MD, cofounder and CEO of Cultura Dermatology & Laser Center in Washington, DC, and cochair of Skin of Color ...
Despite expanding treatment options for rare glomerular diseases such as immunoglobulin A nephropathy (IgAN) and focal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results